Medpace price target raised to $250 from $240 at Baird

Baird raised the firm’s price target on Medpace to $250 from $240 and keeps a Neutral rating on the shares. The firm said there’s much more to like on Medpace than not, and none of this changed recently. They find superiority in the company’s uber-consistent strategy and focus, pure organic approach, leading growth, balance sheet, and cash flow profile, GAAP reporting quality, and more. But they admit, they have been incorrectly on the sidelines and now wait for a better entry point.